Matthew Rajan, Natalie Marchevsky, Gemma Sinclair, Katie O'Brien, Kimberley Jefferies, Nelly Owino, Bassam Hallis, David Goldblatt, Mary Matheson, Hannah Cuthbertson, Parvinder Aley, Xinxue Liu, Matthew D Snape
BACKGROUND: Three hexavalent (DTaP-IPV-Hib-HepB) vaccines are licensed in Europe, only one of which (Vaxelis, Hex-V), uses a meningococcal outer membrane protein complex as a carrier protein for Hemophilus influenza type b (Hib), creating potential interactions with the meningococcal vaccine 4CMenB. METHODS: In this single-center open-label randomized trial, infants were randomized in a 1:1 ratio to receive Hex-V or an alternative hexavalent vaccine (Infanrix-Hexa, Hex-IH) at 2, 3, and 4 months with 4CMenB (2, 4, and 12 months) in the UK routine immunization schedule...
January 1, 2023: Pediatric Infectious Disease Journal